P-007 Absolute Lymphocyte Count at Day 30 (Not Earlier) and Early CRS Predict Delayed Responses to Teclistamab: Results From the US Myeloma Immunotherapy Consortium

IF 2.7 4区医学 Q2 HEMATOLOGY

Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI:10.1016/S2152-2650(24)01910-4

Rahul Banerjee, Gurbakhash Kaur, Beatrice Razzo, Andrew Portuguese, Surbhi Sidana, Tiffany Richards, Ariel Grajales-Cruz, Shambavi Richard, Leyla Shune, Jack Khouri, Danai Dima, Hans Lee, Krina Patel, Mariola Vazquez-Martinez, Doris Hansen, James Davis, Hamza Hashmi, Shebli Atrash, Christopher Ferreri, Kelley Julian, Alfred Garfall

引用次数: 0

查看原文本刊更多论文

P-007 第30天（而非更早）的绝对淋巴细胞计数和早期CRS可预测对替卡单抗的延迟反应：美国骨髓瘤免疫疗法联盟的研究结果

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.